Abstract 960P
Background
HCC is an aggressive malignancy, accounting for ∼90% of primary hepatic cancers. While surgical resection and liver transplantation (Tx) can be curative, 8-20% of post-Tx and 40-70% of post-resection patients recur. Here we sought to analyze the utility of longitudinal testing with ctDNA in patients (pts) with HCC.
Methods
This multicenter study retrospectively analyzed 227 plasma samples from 66 pts with HCC. The curative-intent surgeries included liver Tx (41/66, 62%) and hepatectomy (23/66, 34%); two pts (3%) who were inoperable received liver directed and systemic targeted therapy. Five of the 41 post-Tx pts received additional resection for oligometastatic recurrence prior to ctDNA testing. The cohort was analyzed based on 3 mutually exclusive sub-cohorts: Cohort A (N=34): recurrence monitoring after curative liver Tx; Cohort B (N=25): recurrence monitoring after curative-intent surgical resection; Cohort C (N=7): pts with known recurrence monitored for treatment response/disease progression. Longitudinal ctDNA testing was performed using the SignateraTM bespoke mPCR NGS assay.
Results
The cohort distribution included: 28 (42.4%) / 21 (31.8%) / 7 (10.6%) / 9 (13.6%) stage I/II/III/IV pts with a median age of 67 years (range: 21-84); median follow-up of 584 days (range: 79 - 1537). In cohort A, all patients were ctDNA-negative and remained recurrence-free.In cohort B, postsurgical ctDNA was detected in 9 (36%) patients, 6 experienced clinical recurrence and 3 had limited follow-up. The median lead time of ctDNA detection over clinical recurrence was 52 days (range: 0-262). Among the ctDNA-negative patients (N=16), only one pt experienced clinical recurrence; this was >1 year after the last ctDNA test. In cohort C, on-treatment ctDNA dynamics were concordant with treatment response in 4 pts as measured by imaging. The remaining 3 pts were persistently ctDNA-negative on/shortly after systemic therapy.
Conclusions
Longitudinal testing with ctDNA is critical in identifying early recurrence post surgical resection. Similarly, monitoring treatment response in the palliative setting can help resolve ambiguous imaging results.
Clinical trial identification
N/A
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Brdiges: Financial Interests, Institutional, Advisory Board, Full-time employment and stock or option to own stock at Natera, Inc. Name: Antony Tin: Natera, Inc.. T. Tin, C. Brewer, A. Jurdi, M.C. Liu: Financial Interests, Personal and Institutional, Advisory Board: Natera Inc. All other authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18